Physician profile
Diaz Clark
NPI 1164185468
$763.97
in general payments reported to CMS, 2019-2025
16 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.04 · 2022: $281 · 2023: $122 · 2024: $193 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $137.93 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $134.09 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.40 | 2021-2024 | Jardiance |
| Abbvie INC. | $81.37 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $41.44 | 2023 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $36.84 | 2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $35.36 | 2022-2023 | |
| Exact Sciences Corporation | $31.52 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $24.80 | 2025 | Quviviq |
| Astellas Pharma US INC | $24.36 | 2024 | Veozah |
| Amarin Pharma, INC. | $24.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.45 | 2022 | |
| Viiv Healthcare Company | $19.31 | 2025 | Dovato |
| Eisai INC. | $18.37 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.80 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diaz Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.